
Pre-made Crizanlizumab benchmark antibody ( Whole mAb, anti-SELP therapeutic antibody, Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-123
Pre-Made Crizanlizumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Crizanlizumab, sold under the brand name Adakveo, is a monoclonal antibody medication developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-123-1mg | 1mg | 3090 | ||
GMP-Bios-ab-123-10mg | 10mg | 21890 | ||
GMP-Bios-ab-123-100mg | 100mg | 148000 | ||
GMP-Bios-ab-123-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Crizanlizumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody |
INN Name | Crizanlizumab |
Target | SELP |
Format | Whole mAb |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | IgG2 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Approved |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2016 |
Year Recommended | 2017 |
Companies | Selexys Pharmaceuticals;Novartis |
Conditions Approved | Vaso-occlusive crisis |
Conditions Active | Priapism;Myelofibrosis;COVID-19 |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
